MA-TAKEDA-PHARMACEUTICAL
1.9.2021 22:33:13 CEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia (AML) improved EFS versus azacitidine alone. An event in the trial is defined as death or transformation to AML in participants with higher-risk MDS or CMML, whichever occurs first, and death in participants with AML.
“While we are disappointed with this outcome, we are continuing to gain a greater understanding of the full data set and hope that findings from this Phase 3 study will provide information to help guide research and development for potential treatment options for these underserved patient populations,” said Chris Arendt, PhD, Head, Oncology Cell Therapy and Therapeutic Area Unit, Takeda. “We would like to thank the patients, families, advocacy organizations and investigators that participated in this trial, without whom this meaningful research would not have been possible. Takeda remains committed to conducting important research and transforming the lives of patients with cancer.”
Full data results will be submitted for presentation at an upcoming medical congress. Investigators have been informed of the outcome so they can discuss the potential impact with study participants. Takeda will work with investigators who will determine the most appropriate action for each individual patient enrolled in the study.
About Pevonedistat
Pevonedistat is a NEDD8-activating enzyme (NAE) inhibitor that leads to cancer cell death by disrupting protein homeostasis. The Phase 3 PANTHER study (Pevonedistat-3001) did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS) and the data results are currently being evaluated. The safety profile was consistent with previously reported data for this combination. Pevonedistat is an investigational drug for which safety and efficacy have not been established.
Takeda’s Commitment to Oncology
Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com
.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK
) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com
.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/
or at www.sec.gov
. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Medical information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005908/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Indra Group Exceeds All Its Guidances in 2025 and Sets Even More Ambitious Guidances for 2026 Than Those Set Out in Its 'Leading the Future' Strategic Plan25.2.2026 23:08:00 CET | Press release
Results in fiscal year 2025Revenues increased by 13%, totaling €5.457 billion in 2025Indra Group sets financial guidances at least 17% higher than those foreseen in its Strategic Plan for 2026Indra Group announces thepayment of a €0.30 dividend per share (more than 20% above the dividend in 2024) charged to the earnings posted in 2025The results and the increase in the order intake confirm Indra Group’s industrial strength and its capacity to tackle and execute the major defence modernization programs Indra Group (MAD:IDR): • The fourth-quarter order intake in 2025 totaled €8.329 billion, raising thefull-year backlog to €16.083 billion (122% more than in 2024). The Defence backlog stood at €11.336 billion, far exceeding the target of more than €10 billion set for 2026. • Revenues increased by 13% in 2025 with respect to 2024, with double-digit year-on-year rises in Defence, ATM and Mobility Revenues recorded a 28% year-on-year rise in the final quarter of the year • EBITDA and EBIT rec
Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series25.2.2026 19:00:00 CET | Press release
Including five ‘Designed for Samsung’ accessories plus more, the collection is engineered and optimized specifically for the Samsung Galaxy S26 seriesFrom fast Qi2 25W charging to Nano-Titan–enhanced screen protection, each product is engineered for everyday performance and durabilityThe lineup reinforces Belkin’s role as a trusted partner for next-generation Galaxy devices Belkin, a leading consumer electronics brand for over 40 years, today announced a new collection of accessories designed and optimized specifically for the Samsung Galaxy S26 series. From fast, reliable Qi2 25W charging to advanced screen protection engineered for ultrasonic fingerprint sensors and next-generation displays, every product in the collection is designed to meet the demands of Galaxy S26 users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225459906/en/ Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series ‘Designed f
Andersen Consulting udvider sine kompetencer med Assure Consulting25.2.2026 18:58:00 CET | Pressemeddelelse
Andersen Consulting styrker sin platform med tilføjelsen af samarbejdspartneren Assure Consulting, et tysk managementkonsulentfirma med speciale i projektledelse og projektporteføljestyring. Assure Consulting blev grundlagt i 2003 og hjælper organisationer med at gennemføre komplekse projekter og transformationer. Firmaet hjælper kunder med at etablere og drive projektkontorer (PMO'er), styrke governance og porteføljestyring samt anvende klassiske, agile eller hybride projektledelsesmetoder, der er skræddersyet til deres behov. Assure Consulting yder også praktisk støtte til udrulning af store systemer og processer, integreret forandringsledelse i forbindelse med organisatoriske og kulturelle transformationer samt coaching- og træningsprogrammer, der er i overensstemmelse med internationalt anerkendte standarder for projektledelse, med henblik på at opbygge bæredygtige kompetencer i kundernes organisationer. "Dette samarbejde giver os mulighed for at skalere vores ekspertise inden for
OLX Launches Agentic AI Products to Transform Property Search and Car Sales at CLAIM AI in Lisbon25.2.2026 15:33:00 CET | Press release
OLX launches CompassGPT and AutoIQ, making OLX the leading verticalised platform scaling Agentic AI across the entire value chain - supporting millions of buyers while simultaneously empowering professional customers. The Agentic Products were unveiled at CLAIM AI in Lisbon, OLX’s premier flagship event, bringing together industry leaders to showcase practical, powerful AI innovation OLX’s leading investments and application of proprietary AI deliver faster, smarter, and more user-centric marketplace experiences, with more than 75 AI use cases already in the market, including 10 agentic AI use cases launched in H126 OLX Group, the largest and fastest growing platform for vertical transactions in Europe and South Africa, today unveiled two new Agentic AI-powered products at CLAIM AI, its invite-only Lisbon conference for marketplace innovators. Launching in key OLX markets, CompassGPT introduces a conversational assistant to real estate search, while AutoIQ provides dealers with automot
KleanNara Partners with Rimini Street to Accelerate Digital Transformation25.2.2026 15:00:00 CET | Press release
South Korea’s leading paper manufacturer cuts SAP ECC 6 and Oracle Database maintenance costs with Rimini Support™, freeing up funds and team focus for AI-driven innovation and growth Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced KleanNara has selected Rimini Street to provide support for its SAP ECC 6 and Oracle Database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225123422/en/ KleanNara Partners with Rimini Street to Accelerate Digital Transformation Founded in 1966, KleanNara is one of South Korea’s leading manufacturers of paper and hygiene products. Holding a 25% share of the white cardboard market, the company is known for its commitment to quality, sustainability and innovation, and continues to expand globally with a focus on ESG-driven, eco-friendly products. Breaki
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
